ArticleMovement disorders clinical practice2026
Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundFracture risk is increased in Parkinson's yet this risk is often not addressed.
objectivesOur objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
methodsThe clinical practice research datalink (CPRD) GOLD data contains anonymized UK primary care data. We identified fragility fractures (hip, vertebrae, wrist/distal radius, humerus, rib, pelvis and unspecified osteoporotic) amongst prevalent parkinsonism patients between 2010 and 2019, and ascertained whether bone protective medications and/or vitamin D/calcium supplements were prescribed in the pre-fracture period or in the 48-weeks post-fracture. Logistic regression was used to determine predictors of prescriptions.
resultsThere were 21,581 people with parkinsonism (mean age 74.7 ± 9.8 years, 40% female), with a mean of 3.1 ± 2.5 years of available data. One thousand eight hundred twenty-three experienced at least one fragility fracture. Prior to a fragility fracture 12% had a prescription for bone protective medication. This increased to 38% and 53% in the 16 and 48-weeks post-fracture, respectively. 24% already had a prescription for vitamin D/calcium which increased to 73% at 48-weeks post-fracture. Female gender (OR = 2.06 [1.69-2.51], p < 0.001) and sustaining a vertebral fracture (OR = 2.06 [1.53-2.77], p < 0.001) increased the odds of bone protection prescriptions. However, sustaining a rib fracture (OR = 0.34 [0.19-0.60], p < 0.001) or residing in a care home (OR = 0.58 [0.38-0.88], p = 0.01) decreased the odds.
conclusionsThere is an osteoporosis treatment gap in Parkinson's rendering an already high-risk population at further risk of fracture. Men and those with rib fractures are two groups who are least likely to receive potentially beneficial treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.